Stock Ratings / Health Care / ETON / options

INVA (75) GPCR (42) PAHC (68) TYRA (41) ⌘ Pro Terminal →

Eton Pharmaceuticals Inc. (ETON) Options Positioning, Max Pain & Unusual Sweeps

$53.67 +3.61% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $53.92

Eton Pharmaceuticals Inc. (ETON) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $1.53B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $53.92 (+0.46%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 12.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY • 54.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+1.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ETON)Realized 20D OHLCV Swing Band: ±9.8%

Deterministic 5-Pillar Attribution (62/100 Composite)

🔍 WHY ETON SCORES 62/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (26% of score)

Altman Z-Score 13.37 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Whale & Options Positioning+14/20 pts (23% of score)

20D Institutional Volume Accumulation (±9.8% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution6/20 pts (-14 pt drag)

Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B$55.21-8.9% Next Q

Q2 (-2Q)

Grade B-$50.31-0.6% Next Q

Q3 (-1Q)

Grade C+$50.00+7.3% Next Q

Current

Grade C$53.67+0.7% Hist 90D α

Trajectory: B (70) → C (62)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ETON Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 62/100 (C) score, ETON faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Dilution Drag (+1.64% YoY Shares) — any gross margin slip below 51.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($56.00) or 200D SMA ($35.71) invalidates the momentum regime and cuts Target Base ($54.64) toward Bear Floor ($42.62).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ETON• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ETON Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 62%NO 38%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±9.8%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ETON)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ETON.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating ETON & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on ETON
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ETON // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +122.51%🛡️ HOLDING TREND SUPPORT

2026-10-30O $53.33H $53.67L $51.89C $53.67VOL 335.7K

RES: $71.01SUP: $50.10SMA50: $56.00SMA200: $35.71

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ETON Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ETON Butterfly Map → + Track ETON →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +104.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ETON today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ETON. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ETON today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ETON)

Health Care Rank #169 of 1016 ⚔️ INVA vs ETON Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ETON vs. INVA, GPCR, PAHC, TYRA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Eton Pharmaceuticals Inc. (ETON) ranks #169 by composite RQD confidence (62/100, grade C) and #303 by equity capitalization ($1.53B). Within this direct 5-issuer industry benchmark cohort, PAHC leads on earnings valuation at 32.7x trailing P/E, while INVA leads on capital efficiency and profitability with 14.7% ROIC and 74.8% gross margin. INVA currently holds the highest overall quantitative score in the immediate peer group at 75/100 (B) compared with ETON at 62/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ETON ACTIVE Eton Pharmaceuticals Inc.	C	62/100	—	53.5%	-0.9%	+3.61%	$1.53B	Benchmark Subject
INVA Innoviva Inc.	B	75/100	—	74.8%	14.7%	+0.90%	$1.54B	/inva-vs-eton →
GPCR Structure Therapeutics Inc.	D-	42/100	—	—	-19.5%	+2.14%	$1.56B	/gpcr-vs-eton →
PAHC Phibro Animal Health Corporation (Class A)	C+	68/100	32.7x	30.9%	9.9%	+2.59%	$1.58B	/pahc-vs-eton →
TYRA Tyra Biosciences Inc.	D-	41/100	—	—	-35.0%	-1.24%	$1.48B	/tyra-vs-eton →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001710340

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Eton Pharmaceuticals Inc. (ETON) reported GAAP revenue of $80.0M (+104.9% vs. FY2024 revenue of $39.0M , and +152.7% cumulative change since FY2023) , GAAP net income of -$4.6M, operating cash flow of $10.5M, and free cash flow of $10.2M (+980.7% YoY). On the balance sheet, ETON closed FY2025 with $92.1M in total assets against $21.8M in total debt (Altman Z-Score: 13.37, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$80.0M	-$4.6M	$10.5M	$10.2M	$92.1M	$21.8M
FY2024 (FY)	2024-12-31	$39.0M	-$3.8M	$969.0K	$943.0K	$76.1M	$29.8M
FY2023 (FY)	2023-12-31	$31.6M	-$936.0K	$6.8M	$6.8M	—	—

3. ETON Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ETON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Eton Pharmaceuticals Inc. (NASDAQ: ETON) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $53.67 (+3.61% 1D, market cap $1.53B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, ETON ranks #169 in composite RQD confidence.

How does ETON compare to INVA and GPCR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ETON carries a Roarable C (62/100 RQD), trailing P/E of N/A, gross margin of 53.5%, and ROIC of -0.9%. By comparison, INVA (Innoviva Inc.) holds a B grade (75/100 RQD, P/E N/A, ROIC 14.7%, cap $1.54B) and GPCR (Structure Therapeutics Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -19.5%, cap $1.56B). Among the 5-stock peer group, PAHC leads on earnings multiple (32.7x) while INVA leads on capital efficiency (14.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ETON?

Per ETON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001710340), Eton Pharmaceuticals Inc. generated $80.0M in revenue (+104.9% YoY), -$4.6M in net income, and $10.2M in free cash flow against $92.1M in total assets and $21.8M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ETON trading relative to its 50-day, 200-day, and 52-week technical levels?

ETON last traded at $53.67 (+3.61% on volume of 369,485 shares), positioning the stock -4.16% below its 50-day simple moving average ($56.00) and +50.29% above its 200-day simple moving average ($35.71). Across its 52-week range of $14.27 to $66.37, ETON sits at the 75.6% percentile with a 14-day RSI of 47.9 (NEUTRAL RANGE) and an implied next-earnings move of ±9.8% ($48.41 to $58.93).

ETON Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ETON's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for ETON.

Direct Sub-Reports: ETON RQD Cockpit ETON 12M Forecast ETON Earnings & Move ETON Dividends & DRIP ETON Insiders & 13F ETON Whale Options ETON Profit Sankey ETON News & Why